Eli Lilly Gets FTZ Green Light for Drug Making in NC
Published Date: 9/25/2026
Notice
Summary
Eli Lilly wants to start making several important drug products at their Concord, North Carolina facility under special Foreign-Trade Zone rules. This move helps them save on import duties for certain materials while producing medicines for diabetes, migraines, inflammation, weight management, and Alzheimer's. The government got their request on September 17, 2026, and is reviewing it to give the green light soon.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Eli Lilly seeks duty-free FTZ production
Eli Lilly notified the Foreign-Trade Zones Board on September 17, 2026 that it wants to produce multiple drug products at its Concord, North Carolina facility within FTZ Subzone 57F. The listed finished products (including incretin-based therapies, CGRP monoclonal antibody products for migraine prevention, IL-17A, IL-13, IL-23 therapies, amylin and amyloid-targeted therapies, and packaged forms in filled syringes, vials, or delivery pens) and listed foreign-status components (including drug substances, vials, syringes, delivery-device parts, and needles) are described as duty free when admitted under FTZ procedures.
Some inputs may still face 232/301 duties
The request states certain materials/components may be subject to duties under section 232 of the Trade Expansion Act of 1962 or section 301 of the Trade Act of 1974 depending on country of origin. Those subject merchandise items must be admitted to FTZs in "privileged foreign status" as described in 19 CFR 146.41.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20775, Foreign-Trade Zone (FTZ) 40, Notification of Proposed Production Activity; Norman Noble Company Inc.; (Implantable Medical Devices); Highland Heights, Ohio
Norman Noble Company in Highland Heights, Ohio, wants to start making implantable medical devices using some imported materials with special trade benefits under Foreign-Trade Zone 40. This move could save money on import duties for parts like tungsten plates and stainless steel tubes. Public comments are open until November 18, 2026, so anyone interested can share their thoughts before the plan moves forward.
2026-20774, Foreign-Trade Zone (FTZ) 16, Notification of Proposed Production Activity; Yazaki North America, Inc.; (Stamped Copper Terminals); Petoskey, Michigan
Yazaki North America wants to start making stamped copper terminals at their Petoskey, Michigan plant using special foreign materials with lower or no import duties. This change could save money on materials like copper and steel alloys, but some parts still face tariffs. People have until November 18, 2026, to share their thoughts before the plan gets the green light.
2026-20776, Foreign-Trade Zone (FTZ) 50, Notification of Proposed Production Activity; Sanyo Denki America, Inc.; (Cooling, Servo, and Power Systems and Assemblies); Torrance, California
Sanyo Denki America in Torrance, California, wants to start making cooling, servo, and power system parts inside Foreign-Trade Zone 50. This means they can use certain imported materials with lower or no import taxes, helping them save money and speed up production. The government is reviewing this plan, which could boost local manufacturing and keep prices competitive.
2026-20253, Foreign-Trade Zone (FTZ) 75; Authorization of Production Activity; Essai, Inc.; (Semiconductor Test Equipment); Chandler, Arizona
Essai, Inc. in Chandler, Arizona, got the green light to make semiconductor test equipment inside Foreign-Trade Zone 75. This means they can produce their high-tech gear with special trade benefits, helping them save money and speed up operations. The approval was finalized on September 28, 2026, so Essai can start or continue their work without any extra delays.
2026-20261, Foreign-Trade Zone (FTZ) 153; Authorization of Limited Production Activity; CMS Circuits, Inc.; (Electronic Manufacturing Services in Aerospace, Industrial, and Medical Applications); Murrieta, California
CMS Circuits, Inc. in Murrieta, California, got the green light to start limited production of electronic parts for aerospace, industrial, and medical uses inside Foreign-Trade Zone 153. This means they can bring in certain fiber optic bundles under special foreign status, but only for two years. The City of San Diego and local businesses will benefit from this move, which could boost local manufacturing and trade.
2026-20254, Foreign-Trade Zone (FTZ) 45; Authorization of Limited Production Activity; Qorvo US, Inc.; (Semiconductor Wafers and Modules); Hillsboro, Oregon
Qorvo US, Inc. in Hillsboro, Oregon got the green light to start limited production of semiconductor wafers and modules in Foreign-Trade Zone 45. This means they can use some imported parts with special rules for two years, helping them save money and speed up manufacturing. The approval came after a careful review and public input, so it’s official and ready to roll!
Previous / Next Documents
Previous: 2026-19698, Foreign-Trade Zone (FTZ) 93, Notification of Proposed Production Activity; Eli Lilly and Company; (Drug Products); Durham, North Carolina
Eli Lilly wants to start making several special drug products at their Durham, North Carolina facility under Foreign-Trade Zone 93. This means they can use certain imported materials without paying duties while producing medicines for diabetes, migraines, inflammation, weight management, and Alzheimer's. The change could speed up production and save money, with the proposal officially received on September 17, 2026.
Next: 2026-19700, Dermatologic and Ophthalmic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-New Drug Application (NDA) 219694 for Atropine Sulfate Ophthalmic Solution, 0.01%
The FDA is holding a public meeting on October 30, 2026, to discuss a new eye drop medicine called Atropine Sulfate Ophthalmic Solution, 0.01%. This meeting lets people share their thoughts before the FDA decides if the drug should be approved. Anyone interested, especially patients and eye care providers, can join online or in person and send comments by October 29, 2026.